Physician

Kelly Jo Parling-Lynch, DO

According to 2025 Medicare claims, Kelly Parling-Lynch, DO (NPI: 1215936158) practices hematology/oncology in the Grand Rapids-Wyoming-Kentwood, MI market, with the plurality of this provider's patient population coming from Ottawa, MI. This provider's primary affiliated billing organization is CANCER & HEMATOLOGY CENTERS OF WESTERN MI, P.C. (NPI: 1528018389; TIN: 382777354) and primary practice location at 49424-8217. Parling-Lynch is affiliated with the Trinity Health Integrated Care (ACO ID: A3454) and West Michigan Accountable Care Organization, LLC (ACO ID: A4626), participating under the MSSP model.

Parling-Lynch's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 321 traditional Medicare patients, billed 101,882 HCPCS/CPT codes, and received $1,813,526 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,686 prescription claims across 437 beneficiaries totaling $4,362,391 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 27 claims. Open Payments data shows 154 records totaling $3,363. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	274	19,012	$255,979
2016	604	117,852	$2,181,827
2017	791	204,459	$3,152,369
2018	710	221,264	$2,843,775
2019	671	176,542	$2,564,308
2020	607	143,496	$2,687,569
2021	489	136,624	$2,381,851
2022	361	98,809	$1,679,851
2023	342	131,154	$1,770,195
2024	321	101,882	$1,813,526

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	162	580	$205,551
2016	343	1,532	$1,302,755
2017	455	2,546	$3,201,052
2018	500	3,016	$5,067,542
2019	452	2,734	$5,957,629
2020	488	2,887	$5,829,518
2021	488	2,614	$5,038,014
2022	442	2,369	$4,027,938
2023	425	2,401	$3,652,738
2024	437	2,686	$4,362,391

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	30	$10,993
2017	N/R	56	$17,218
2018	N/R	67	$12,678
2019	N/R	62	$5,350
2020	N/R	54	$4,349
2021	N/R	83	$6,898
2022	N/R	N/R	N/R
2023	N/R	27	$1,168
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	90	158	$92
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	88	118	$64
80053	Blood test, comprehensive group of blood chemicals	121	563	$10
36415	Insertion of needle into vein for collection of blood sample	162	923	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	161	882	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	46	1,218	$756,230
Pomalyst	Pomalidomide	19	532	$435,818
Alecensa	Alectinib Hcl	23	690	$380,691
Tagrisso	Osimertinib Mesylate	21	630	$364,577
Lenalidomide	Lenalidomide	22	616	$327,782

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	154	$3,363	Genentech USA, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Kelly Jo Parling-Lynch, DO?

Tedicare shows public-source Medicare data for Kelly Jo Parling-Lynch, DO (NPI 1215936158), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Kelly Jo Parling-Lynch, DO have ACO affiliation data?

Kelly Jo Parling-Lynch, DO is shown with ACO affiliation data for Trinity Health Integrated Care (MSSP, ACO ID A3454) and West Michigan Accountable Care Organization, LLC (MSSP, ACO ID A4626).

What billing organization is linked to Kelly Jo Parling-Lynch, DO?

Kelly Jo Parling-Lynch, DO is linked to CANCER & HEMATOLOGY CENTERS OF WESTERN MI, P.C. (billing NPI 1528018389) in the available physician profile data.

Does Kelly Jo Parling-Lynch, DO have Open Payments data?

Kelly Jo Parling-Lynch, DO has 154 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.